Xeris Biopharma Holdings (XERS) Interest & Investment Income (2020 - 2026)

Xeris Biopharma Holdings has reported Interest & Investment Income for 7 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income rose 2.3% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (up 4.29% YoY), and the FY2025 full-year result was $4.7 million, down 10.88% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $1.2 million, down from $1.5 million in the prior quarter.
• The five-year high for Interest & Investment Income was $1.9 million in Q1 2024, with the low at $68000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $1.1 million across 5 years, with a median of $1.2 million in 2025.
• Annual changes were most pronounced in 2022 — Interest & Investment Income surged 2532.86% — and 2023, when it slumped 39.93%.
• Xeris Biopharma Holdings' Interest & Investment Income stood at $1.8 million in 2022, then plunged by 39.93% to $1.1 million in 2023, then decreased by 17.8% to $910000.0 in 2024, then surged by 60.55% to $1.5 million in 2025, then fell by 17.73% to $1.2 million in 2026.
• The last three Interest & Investment Income figures came in at $1.2 million (Q1 2026), $1.5 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.